J. Cooper

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

J. Burke, R. Advani, B. Cheson, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

R. Fonseca, A. Krishnan, S. Trudel, 2020 .

A Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia

Connie Y. C. Ma, N. Daver, K. Yee, 2021, American journal of hematology.

Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Sean P. Lear, S. Trudel, H. Koeppen, 2020 .

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

R. Fonseca, A. Krishnan, S. Trudel, 2021, Blood.

Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients

Connie Y. C. Ma, A. Logan, B. Gjertsen, 2021, European journal of haematology.

A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lamotrigine in the maintenance treatment of Chinese adult patients with bipolar I disorder

Ling Zhang, G. Wang, Xiufeng Xu, 2021, International Journal of Bipolar Disorders.

Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

R. Fonseca, A. Krishnan, S. Trudel, 2022, Blood.